Chief Strategy Officer & Head of Operations
Dr. Devyn Smith is Sigilon Therapeutics’s Chief Strategy Officer and Head of Operations. In this role, Dr. Smith is tasked with building the strategy and operational elements for a portfolio of potential new medicines
Before joining Sigilon Therapeutics, Dr. Smith was part of Pfizer’s Medicinal Sciences Division of R&D, where he was Head of Business Operations & Strategy. His responsibilities in this position included oversight of both the day-to-day business operations of the division and the development of implementable strategies. Dr. Smith also held several other high-level positions at Pfizer including Head of Strategy for the Pharmatherapeutics Division of Pfizer R&D and Chief Operating Officer of Pfizer’s Neusentis Research Unit in the UK. He also supported the Pharmatherapeutics Global Clinical Research Organization as Chief Operating Officer. Before his time at Pfizer, Dr. Smith was a principal for management consulting firm, The Frankel Group. During this period, his clients ranged from large pharmaceutical to small biotech companies. Throughout his career, Regenerative Medicine has been a strong area of focus of Dr. Smith’s research.He has published multiple papers and delivered over 50 invited conference presentations at cell therapy meetings related to the subject.
Dr. Smith received his Ph.D. in Genetics from Harvard Medical School where his research culminated in 12 publications in leading journals such as Cell, Nature, and Development. He also holds an M.S. in Biology from Idaho State University and a B.S. in Zoology from Brigham Young University.